Acrux (ARUXF) ROCE % : -91.20% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Acrux ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Acrux's annualized ROCE % for the quarter that ended in Dec. 2023 was -91.20%.

Acrux ROCE % Historical Data

The historical data trend for Acrux's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux ROCE % Chart

Acrux Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-47.75

-64.72

-94.88

-77.75

-30.27

Acrux Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-72.82	-93.99	-102.23	32.52	-91.20

Acrux ROCE % Calculation

Acrux's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-2.275	/	( ( (10.051 - 2.332)	+	(8.916 - 1.604) )	/ 2 )
	=	-2.275	/	( (7.719	+	7.312)	/ 2 )
	=	-2.275	/	7.5155
	=	-30.27 %

Acrux's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-5.662	/	( ( (8.916 - 1.604)	+	(8.043 - 2.938) )	/ 2 )
	=	-5.662	/	( ( 7.312	+	5.105 )	/ 2 )
	=	-5.662	/	6.2085
	=	-91.20 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Acrux (OTCPK:ARUXF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Acrux ROCE % Related Terms

Thank you for viewing the detailed overview of Acrux's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acrux (ARUXF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (OTCPK:ARUXF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

FJY:Germany ACR:Australia

Address

103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003

Website

https://www.acrux.com.au

Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.

Acrux (ARUXF) Headlines

No Headlines